Skip to content

Frontlight ResearchEarly access

Trial site

Anhui Provincial Hospital

Hefei, 230036, ChinaNot linked to an institution yet

121running trials
35closed trials

The trials here

What the 156 trials at this site are about, from their registry records.

Conditions: Liver and biliary tract cancer25 trials
Lung cancer23 trials
Gastric and oesophageal cancer10 trials
Haemophilia9 trials
Lupus (SLE)7 trials
Metastatic breast cancer6 trials
Childhood cancers5 trials
Chronic lymphocytic leukaemia5 trials
Rheumatoid arthritis5 trials
Acute myeloid leukaemia4 trials
Alzheimer disease4 trials
Dermatomyositis and polymyositis (myositis)4 trials
and 39 more
Phase: Phase 376 trials
Phase 230 trials
Phase 1/212 trials
Phase 2/311 trials
Phase 17 trials
Early phase 13 trials
Phase 42 trials
Status: Recruiting53 trials
Active, not recruiting40 trials
Completed32 trials
Not yet recruiting27 trials
Terminated3 trials
Enrolling by invitation1 trial
Lead sponsor: BeiGene10 trials
Anhui Provincial Hospital9 trials
Chia Tai Tianqing Pharmaceutical Group Co., Ltd.8 trials
Eli Lilly and Company7 trials
Hoffmann-La Roche7 trials
and 84 more

Running trials

Not yet recruiting
A Study to Understand How Nerandomilast Works in People With Active Idiopathic Inflammatory Myopathies
NCT07789015· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Not yet recruiting
Phase III Study of HS-20089 With Bevacizumab in Platinum-Sensitive Recurrent Ovarian Cancer
NCT07821606· Phase 3· Hansoh BioMedical R&D Company· Source
Contact: Ding Ma, PhD
Recruiting
Study Evaluation Rentosertib (INS018_055) Administered Orally in Patients With Idiopathic Pulmonary Fibrosis (IPF)
NCT07687459· Phase 3· InSilico Medicine Hong Kong Limited· Source
Contact: Qinhan Chen
Recruiting
Efficacy and Safety of Telitacicept in the Treatment of Refractory Rheumatoid Arthritis
NCT07796516· Phase 2· Peking University People's Hospital· Source
Contact: Zhu Chen
Recruiting
A Phase 2b Clinical Trial of YN001 in Adults With Coronary Atherosclerosis
NCT07521007· Phase 2· Beijing Inno Medicine Co., Ltd.· Source
Contact: Kangyu Chen, MD
Recruiting
A Study to Test Whether Nerandomilast Helps People With Systemic Sclerosis
NCT07497087· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Not yet recruiting
A Phase II Study of H021 Enteric-coated Tablets for Moderately to Severely Active Crohn's Disease
NCT07677514· Phase 2· Jiangsu Carephar Pharmaceutical Co., Ltd.· Source
Contact: zhengyu song
Active, not recruiting
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) as Prophylactic Treatment.
NCT07684898· Phase 3· Hangzhou Gensciences Biopharmaceutical Co., Ltd.· Source
Recruiting
RO7771950 Versus Tucatinib in Combination With Trastuzumab and Capecitabine in People With Locally Advanced or Metastatic Breast Cancer That is Human Epidermal Growth Factor Receptor 2 (HER2)-Positive
NCT07413939· Phase 2/3· Hoffmann-La Roche· Source
Recruiting
A Phase Ib/II Trial to Evaluate the Efficacy and Safety of HH-009 for the Treatment of FGF19-positive Advanced or Unresectable HCC
NCT07547553· Phase 1/2· Huahui Health· Source
Contact: Xiyu Zhang PM
Recruiting
Donanemab (LY3002813) Trial in Chinese Participants With Cognitively Unimpaired (Preclinical) Alzheimer's Disease
NCT07571161· Phase 3· Eli Lilly and Company· Source
Contact: Zhaozhao Cheng (principal investigator)
Active, not recruiting
Study of Recombinant Human Coagulation Factor VIII-Fc Fusion Protein (FRSW107) On-Demand Treatment
NCT07663903· Phase 3· Hangzhou Gensciences Biopharmaceutical Co., Ltd.· Source
Recruiting
A Study of Nipocalimab in Adults With Moderate to Severe Systemic Lupus Erythematosus
NCT07438496· Phase 3· Janssen Research & Development, LLC· Source
Recruiting
A Phase Ib/II Study of ATG-022 Plus Pembrolizumab With/Without Chemotherapy in Participants With Claudin (CLDN) 18.2-positive, HER2-negative, Unresectable or Metastatic Gastric or Gastroesophageal Junction AdenocarcinomaUnresectable or Metastatic Gastric or Gastroesophageal Junction Adenocarcinoma
NCT07327229· Phase 1/2· Antengene Biologics Limited· Source
Contact: Gang Wang
Recruiting
A Study of LY4298445 in Healthy Participants and Participants With Systemic Lupus Erythematosus (SLE) or Rheumatoid Arthritis (RA)
NCT07276958· Phase 1· Eli Lilly and Company· Source
Contact: Zhu CHEN (principal investigator)
Not yet recruiting
Efficacy and Safety of TT-00420 (Tinengotinib) Tablets Versus Chemotherapy in Patients With Advanced Intrahepatic Cholangiocarcinoma Harboring FGFR2 Fusions/Rearrangements or Mutations
NCT07328919· Phase 3· TransThera Sciences (Nanjing), Inc.· Source
Contact: Caixia Sun
Recruiting
Study to Evaluate Efficacy and Safety of Firmonertinib Compared With Investigator's Choice of EGFR Inhibitor as First-Line Treatment in Participants Who Have Locally Advanced or Metastatic NSCLC With EGFR P-Loop and Alpha C-Helix Compressing (PACC) Uncommon Mutations
NCT07185997· Phase 3· ArriVent BioPharma, Inc.· Source
Contact: Clinical Trials
Recruiting
A Study of ZL-1310 Versus Investigator's Choice of Therapy in Participants With Relapsed Small Cell Lung Cancer (DLLEVATE)
NCT07218146· Phase 3· Zai Lab (Shanghai) Co., Ltd.· Source
Recruiting
A Study Comparing TAK-928 With Docetaxel in Adults With Non-Small Cell Lung Cancer
NCT07217301· Phase 3· Takeda· Source
Contact: Yong Wang
Recruiting
The Treatment of Liver Injury After Liver Resection With Polyene Phosphatidylcholine
NCT07150624· Phase 4· Anhui Provincial Hospital· Source
Contact: Lianxin LIU L LIU
Recruiting
Evaluation of the Safety and Effectiveness of CHORDS® Cerebral Protection System During TAVR: DUET Trial
NCT07648693· Resonova (Shanghai) Medtech Limited· Source
Contact: Yu Tai
Recruiting
Study of Trastuzumab Deruxtecan, Pembrolizumab, and Platinum-based Chemotherapy in First-line HER2 Overexpressing Non-small Cell Lung Cancer
NCT06899126· Phase 3· Daiichi Sankyo· Source
Recruiting
A Study to Learn About the Medicine Ponsegromab in Adults With Cancer of the Pancreas Which Has Spread and Caused Significant Body Weight Loss and Fatigue
NCT06989437· Phase 2/3· Pfizer· Source
Recruiting
CLEOPATTRA: A Research Study to Look at the Effects of Treatment With a Medicine Called Coramitug (NNC6019-0001) in People With Heart Failure Due to Transthyretin Amyloid (ATTR) Amyloidosis
NCT07207811· Phase 3· Novo Nordisk A/S· Source
Contact: Novo Nordisk
Recruiting
A Study to Learn About the Study Medicine Called PF-08046054/SGN-PDL1V Versus Docetaxel in Adult Participants With Previously-Treated Programmed Cell Death Ligand 1 (PD-L1) Positive Non-Small-Cell Lung Cancer (NSCLC)
NCT07144280· Phase 3· Pfizer· Source
Recruiting
To Explore the Safety and Efficacy of Hypervision Proton Surgery for Early-stage Non-small Cell Lung Cancer
NCT07195084· Anhui Provincial Cancer Hospital· Source
Contact: Shuanghu Yuan, PhD
Active, not recruiting
A Study of Trontinemab in Participants With Early Symptomatic Alzheimer's Disease
NCT07169578· Phase 3· Hoffmann-La Roche· Source
Recruiting
A Study of Izalontamab Brengitecan Versus Chemotherapy in Participants With Previously Untreated, Locally Advanced, Recurrent Inoperable, or Metastatic Triple-negative Breast Cancer Ineligible for Anti-PD(L)1 Drugs (IZABRIGHT-Breast01)
NCT06926868· Phase 2/3· Bristol-Myers Squibb· Source
Contact: Nannan Lu, Site 1002
Recruiting
Safety and Efficacy of Metabolically Armed Tumor-lnfiltrating Lymphocytes (Meta10-TIL) for the Treatment of Advanced Solid Tumors
NCT07106814· Early phase 1· Anhui Provincial Hospital· Source
Contact: Fanzheng Meng, Ph.D
Recruiting
A First-in-human, Dose Escalation and Indication Expansion Study of BNT3212 as Monotherapy or in Combination With BNT327 in Adults With Advanced Solid Tumors
NCT07147348· Phase 1/2· BioNTech SE· Source
Recruiting
Anti CD19/BCMA CAR Gene Therapy for Autoimmune Diseases
NCT07121777· Anhui Provincial Hospital· Source
Contact: chen zhu, M.D
Enrolling by invitation
A Study of HB0025 Plus Nab-paclitaxel as First Line Therapy for TNBC
NCT07376629· Phase 2· Huabo Biopharm Co., Ltd.· Source
Recruiting
MDN-001 Injection for the Treatment of Unresectable Primary Hepatocellular Carcinoma.
NCT07391839· Phase 1· Suzhou Mednovo Yi Medical Technology Co., Ltd.· Source
Contact: Hongzhang Zhang
Not yet recruiting
Definitive Proton Radiotherapy Combined With Chemotherapy and Immunotherapy for Locally Advanced Esophageal Squamous Cell Carcinoma: A Phase I Clinical Study
NCT07034118· Phase 1· Anhui Provincial Hospital· Source
Contact: Dong Qian, M.D. & Ph.D.
Recruiting
EASi-PROTKT™ - A Study to Test Vicadrostat (BI 690517) Taken Together With Empagliflozin in People With Type 2 Diabetes, High Blood Pressure, and Cardiovascular Disease
NCT07064473· Phase 3· Boehringer Ingelheim· Source
Contact: Boehringer Ingelheim
Recruiting
CAR-T Cells Therapy for Patients With Autoimmune Diseases
NCT07052565· Anhui Provincial Hospital· Source
Contact: chen zhu, M.D
Recruiting
A Clinical Study of TQB2102 Versus Docetaxel Plus Trastuzumab and Pertuzumab in the Treatment of HER2 Positive Recurrent or Metastatic Breast Cancer
NCT07003074· Phase 3· Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Co., Ltd.· Source
Contact: Nannan Lu, Doctor
Recruiting
Safety and Efficacy of Metabolically Armed BCMA CAR-T Cells (Meta10-BCMA) in the Treatment of r/r Plasma Cell Neoplasms Clinical Research
NCT07085559· Early phase 1· Anhui Provincial Hospital· Source
Contact: Xingbing Wang, PhD
Recruiting
Effect and Safety of Benzathine Penicillin Combined With Etanercept on Spondyloarthritis
NCT06707194· Phase 4· Nanfang Hospital, Southern Medical University· Source
Contact: Jun Xiao
Recruiting
A Clinical Study of the Anti-cancer Effects of an Investigational Therapy or Chemotherapy in Patients With Recurring Uterine Cancer
NCT06340568· Phase 3· BioNTech SE· Source
Not yet recruiting
Real-world Study on Liver Cancer Risk in Chronic Hepatitis B Patients With Family History of Liver Cancer
NCT07007286· Peking University First Hospital· Source
Contact: Hongliang He
Recruiting
Real World Clinical Outcomes of Resected ALK-Positive Early Stage NSCLC Patients Treated With Alectinib as Adjuvant Therapy
NCT06862869· Hoffmann-La Roche· Source
Recruiting
A Study of Adagrasib Plus Pembrolizumab Plus Chemotherapy vs. Placebo Plus Pembrolizumab Plus Chemotherapy in Participants With Previously Untreated Non-squamous Non-small Cell Lung Cancer With KRAS G12C Mutation (KRYSTAL-4)
NCT06875310· Phase 3· Mirati Therapeutics Inc.· Source
Contact: Junqiang Zhang, Site 0475
Active, not recruiting
The Efficacy and Safety of Efsubaglutide Alfa Injection in Overweight and Obese Subjects (ENLIGHT)
NCT06921486· Phase 2/3· Shanghai Yinnuo Pharmaceutical Technology Co., Ltd.· Source
Recruiting
To Evaluate the Clinical Study of GS1191-0445 Injection in the Treatment of Hemophilia A
NCT06833983· Phase 3· Gritgen Therapeutics Co., Ltd.· Source
Contact: Changcheng Zheng
Active, not recruiting
Phase III Clinical Trial of STSP-0601 for Injection in Hemophilia Patients
NCT06922045· Phase 3· Jiangsu BioJeTay Biotechnology Co., Ltd.· Source
Recruiting
A Study to Assess the Efficacy and Safety of Induction and Maintenance Therapy With Afimkibart (RO7790121) in Participants With Moderately to Severely Active Crohn's Disease
NCT06819878· Phase 3· Hoffmann-La Roche· Source
Not yet recruiting
Deep Sedation in Catheter Ablation of Atrial Fibrillation
NCT06836999· The First Affiliated Hospital of Dalian Medical University· Source
Contact: Hao Su
Not yet recruiting
Clinical Trial of TQB3702 Tablets in Subjects With Systemic Lupus Erythematosus (SLE)
NCT06859931· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Contact: Zhu Chen, Doctor
Recruiting
Safety and Efficacy of BNT327, an Investigational Therapy in Combination With Chemotherapy for Patients With Untreated Small-cell Lung Cancer
NCT06712355· Phase 3· BioNTech SE· Source

Showing 50 of 121.

Recruiting at the same time

How many trials recruit for the same indication here at once. A count, not a rating.

Lung cancer14 recruiting
Liver and biliary tract cancer13 recruiting
Gastric and oesophageal cancer7 recruiting
Lupus (SLE)6 recruiting
Rheumatoid arthritis4 recruiting
Dermatomyositis and polymyositis (myositis)3 recruiting
Endometrial cancer3 recruiting
Metastatic breast cancer3 recruiting
Prostate cancer3 recruiting
Systemic sclerosis (scleroderma)3 recruiting
Acute myeloid leukaemia2 recruiting
Amyloidosis2 recruiting
Childhood cancers2 recruiting
Chronic lymphocytic leukaemia2 recruiting
Crohn's disease2 recruiting
Hepatitis B2 recruiting
Multiple myeloma2 recruiting
Pancreatic cancer2 recruiting
Triple-negative breast cancer2 recruiting
Acute lymphoblastic leukaemia1 recruiting
Alzheimer disease1 recruiting
Ankylosing spondylitis1 recruiting
Atrial fibrillation1 recruiting
Brain metastases1 recruiting
Cervical cancer1 recruiting
Chronic myeloid leukaemia1 recruiting
Colorectal cancer1 recruiting
Coronary artery disease1 recruiting
Follicular lymphoma1 recruiting
Haemophilia1 recruiting
Heart failure1 recruiting
High blood pressure1 recruiting
Idiopathic pulmonary fibrosis1 recruiting
Kidney cancer1 recruiting
Mantle cell lymphoma1 recruiting
Migraine1 recruiting
Neuroendocrine tumours1 recruiting
Neuromyelitis optica (NMOSD)1 recruiting
Ovarian cancer1 recruiting
Sarcoma1 recruiting
Stroke1 recruiting
Thyroid cancer1 recruiting
Type 2 diabetes1 recruiting

Closed trials

Terminated
A Study Investigating the Efficacy and Safety of BGB-45035 Versus Placebo in Adults With Moderate to Severe Active Rheumatoid Arthritis
NCT07100938· Phase 2· BeiGene· Source
Completed
Construction and Empirical Study of Indirect Intervention Model for Protective Medical Lung Cancer Patients Based on Family System Theory
NCT07749443· Anhui Medical University· Source
Completed
A Study to Test Whether BI 1819479 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT06335303· Phase 2· Boehringer Ingelheim· Source
Completed
Safety and Efficacy of STSP-0601 in Adult Patients with Hemophilia a or B with Inhibitor
NCT06289166· Phase 2· Staidson (Beijing) Biopharmaceuticals Co., Ltd· Source
Completed
RC88 in Platinum-Resistant Recurrent Epithelial Ovarian Cancer, Fallopian Tube Cancer, and Primary Peritoneal Cancer
NCT06173037· Phase 2· RemeGen Co., Ltd.· Source
Completed
Phase 3 Clinical Project of Pegylated Recombinant Human Coagulation Factor VIII-Fc Fusion Protein
NCT06142552· Phase 3· Hangzhou Gensciences Biopharmaceutical Co., Ltd.· Source
Completed
Efficacy and Safety of Berberine Ursodeoxycholate (HTD1801) in Patients With Type 2 Diabetes Inadequately Controlled With Metformin
NCT06353347· Phase 3· Shenzhen HighTide Biopharmaceutical Ltd.· Source
Completed
A Study to Evaluate LBL-007 in Combination With Tislelizumab Plus Chemotherapy in Participants With Unresectable Locally Advanced or Metastatic Esophageal Squamous Cell Carcinoma
NCT06010303· Phase 2· BeiGene· Source
Completed
SS109 and NovoSeven ® PK / PD Profile, and Preliminary Efficacy and Safety of SS109 on Demand Treatment
NCT06010953· Phase 1/2· Hangzhou Gensciences Biopharmaceutical Co., Ltd.· Source
Completed
Safety and Efficacy of TareSphere in Patients With Unresectable Hepatocellular Carcinoma
NCT06310590· Phase 1· Chengdu New Radiomedicine Technology Co. LTD.· Source
Completed
A Study to Evaluate the Efficacy and Safety of Telitacicept in Subjects With Active Primary Sjogren's Syndrome
NCT05673993· Phase 3· RemeGen Co., Ltd.· Source
Completed
Study of Telitacicept in Generalized Myasthenia Gravis
NCT05737160· Phase 3· RemeGen Co., Ltd.· Source
Completed
Efficacy and Safety of Fruquintinib in Combination With Sintilimab in Advanced Renal Cell Carcinoma (FRUSICA-2)
NCT05522231· Phase 2/3· Hutchmed· Source
Completed
A Study to Investigate the Efficacy and Safety of Efgartigimod PH20 SC in Adult Participants With Active Idiopathic Inflammatory Myopathy.
NCT05523167· Phase 2/3· argenx· Source
Completed
A Study to Find Out Whether BI 1015550 Improves Lung Function in People With Idiopathic Pulmonary Fibrosis (IPF)
NCT05321069· Phase 3· Boehringer Ingelheim· Source
Terminated
TQ05105 Tablet for Myelofibrosis Treatment in Ruxolitinib-Resistant or Intolerant Patients
NCT06388759· Phase 1· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Completed
PM8002 in Combination With Chemotherapy as First Line Therapy in Hepatocellular Carcinoma
NCT05864105· Phase 2· Biotheus Inc.· Source
Terminated
To Evaluate the Efficacy and Safety of Parsaclisib and Ruxolitinib in Participants With Myelofibrosis (LIMBER-313)
NCT04551066· Phase 3· Incyte Corporation· Source
Recruiting
Study of SLS009 (Formerly GFH009) a Potent Highly Selective CDK9 Inhibitor in Patients With Hematologic Malignancies and High-Risk Newly Diagnosed AML
NCT04588922· Phase 1/2· Sellas Life Sciences Group· Source
Contact: James Dean
Completed
Zanubrutinib in Participants With Active Proliferative Lupus Nephritis
NCT04643470· Phase 2· BeiGene· Source
Completed
A Study of Tiragolumab in Combination With Atezolizumab Plus Pemetrexed and Carboplatin/Cisplatin Versus Pembrolizumab Plus Pemetrexed and Carboplatin/Cisplatin in Participants With Previously Untreated Advanced Non-Squamous Non-Small Cell Lung Cancer
NCT04619797· Phase 2/3· Hoffmann-La Roche· Source
Completed
Evaluate the Safety and Efficacy of Toripalimab Combined With Bevacizumab Versus Sorafenib Therapy for HCC
NCT04723004· Phase 3· Shanghai Junshi Bioscience Co., Ltd.· Source
Completed
A Study of ZW25 (Zanidatamab) in Subjects With Advanced or Metastatic HER2-Amplified Biliary Tract Cancers
NCT04466891· Phase 2· Jazz Pharmaceuticals· Source
Completed
A Study of TQB2450 Injection Combined With Anlotinib Hydrochloride Capsule in Subjects With Advanced Endometrial Cancer
NCT04574284· Phase 2· Chia Tai Tianqing Pharmaceutical Group Co., Ltd.· Source
Completed
Preliminary Antitumor Activity, Safety and Tolerability of Tislelizumab in Combination With Lenvatinib for Hepatocellular Carcinoma
NCT04401800· Phase 2· BeiGene· Source
Completed
The Study for CML Who Failed Prior TKIs or With T315I Mutation or Ph+ ALL Who Failed Prior TKIs or With T315I Mutation
NCT04233346· Phase 2· Otsuka Beijing Research Institute· Source
Completed
A Study of E7090 in Participants With Unresectable Advanced or Metastatic Cholangiocarcinoma With Fibroblast Growth Factor Receptor (FGFR) 2 Gene Fusion
NCT04238715· Phase 2· Eisai Co., Ltd.· Source
Completed
Comparison of Gd-EOB-DTPA-enhanced MRI and Contrast-enhanced Ultrasound for Measuring Tumor Size of Solitary Hepatocellular Carcinoma ≤ 5cm:A Retrospective Study
NCT06437457· Anhui Medical University· Source
Completed
Trastuzumab Deruxtecan (DS-8201a) Versus Investigator's Choice for HER2-low Breast Cancer That Has Spread or Cannot be Surgically Removed [DESTINY-Breast04]
NCT03734029· Phase 3· Daiichi Sankyo· Source
Completed
A Study of Tislelizumab (BGB-A317) in Combination With Chemotherapy as First Line Treatment in Participants With Advanced Esophageal Squamous Cell Carcinoma
NCT03783442· Phase 3· BeiGene· Source
Completed
A Maintenance Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis
NCT03524092· Phase 3· Eli Lilly and Company· Source
Completed
An Induction Study of Mirikizumab in Participants With Moderately to Severely Active Ulcerative Colitis (LUCENT 1)
NCT03518086· Phase 3· Eli Lilly and Company· Source
Completed
A Study of Tislelizumab Versus Sorafenib in Participants With Unresectable Hepatocellular Carcinoma (HCC)
NCT03412773· Phase 3· BeiGene· Source
Completed
Comparison of Efficacy and Safety of Tislelizumab (BGB-A317) Versus Docetaxel as Treatment in the Second- or Third-line Setting in Participants With Non-Small Cell Lung Cancer (NSCLC)
NCT03358875· Phase 3· BeiGene· Source
Completed
Image Fusion of SPECT MPI and Fluoroscopy Venography to Guide LV Lead Placement for Improved CRT Response (GUIDE-CRT II)
NCT03125720· The First Affiliated Hospital with Nanjing Medical University· Source

Site data: ClinicalTrials.govUpdated 15 Nov 2026

Report an error